BIO-TECHNE Corp AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax
BIO-TECHNE Corp (TECH) had AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax of $8.39 million as of 2014-03-31, per its 10-Q filed 2014-05-12.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2014-05-12
- 2014-03-31: AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax $8.39M.
- 2013-12-31: AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax $3.08M.
- 2013-09-30: AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax $2.06M.
- 2013-06-30: AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax $38.83M.
| Period end | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax |
|---|---|
| 2014-03-31 | $8.39M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $3.08M 10-Q · filed 2014-02-04 |
| 2013-09-30 | $2.06M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $38.83M 10-Q · filed 2014-05-12 |
| 2013-03-31 | $37.81M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $25.96M 10-Q · filed 2013-02-11 |
| 2012-09-30 | $28.96M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $42.52M 10-K · filed 2013-08-29 |
| 2012-03-31 | $24.53M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $641.00K 10-Q · filed 2012-02-07 |
| 2011-09-30 | $620.00K 10-Q · filed 2011-11-09 |
| 2011-06-30 | $648.00K 10-K · filed 2013-08-29 |
| 2010-06-30 | $733.00K 10-K · filed 2012-08-29 |
| 2009-06-30 | $558.00K 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |